Get to know our clinical trials

Clinical trial of Debio 1143 in combination with platinum derivative chemotherapy and radiotherapy in patients with locally advanced head and neck squamous cell carcinoma suitable for definitive chemoradiotherapy.

THE MAIN OBJECTIVE OF THIS STUDY IS TO FIND OUT HOW WELL DEBIO 1143 WORKS AND HOW SAFE IT IS COMPARED TO A PLACEBO. A PLACEBO IS AN INACTIVE SUBSTANCE THAT LOOKS LIKE THE STUDY DRUG, BUT DOES NOT CONTAIN ANY ACTIVE DRUG. RESEARCHERS USE A PLACEBO TO SEE IF THE STUDY DRUG WORKS BETTER OR IF IT IS AS SAFE AS TAKING NOTHING.

Status
In recruitment
headquarters
Pamplona

Technical Summary

  • PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF DEBIO 1143 IN COMBINATION WITH PLATINUM DERIVATIVE CHEMOTHERAPY AND CONVENTIONAL FRACTIONATION INTENSITY-MODULATED RADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA SUITABLE FOR DEFINITIVE CHEMORADIOTHERAPY (TRILYNX).
  • Code EudraCT: 2020-000377-25
  • Protocol number: Debio 1143-SCCHN-301
  • Promoter: Debiopharm International S.A.
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.